- Johnson & Johnson's (JNJ, Financial) SunRISe-1 trial delivers promising results for bladder cancer treatment.
- Analysts set an average price target with a substantial potential upside.
- GF Value analysis indicates a favorable future valuation for JNJ.
Johnson & Johnson (JNJ) has unveiled encouraging results from its Phase 2b SunRISe-1 trial, showing remarkable promise for its TAR-200 treatment in bladder cancer patients. Impressively, over 82% of participants achieved a complete response, with more than half remaining cancer-free after one year, underscoring the therapy's significant potential.
Wall Street Analysts Forecast
Wall Street's analysts have weighed in with one-year price targets for Johnson & Johnson (JNJ, Financial), reflecting a positive sentiment. With insights from 24 analysts, the average target price stands at $170.64. It features a high estimate of $185.00 and a low estimate of $150.00, suggesting a promising upside potential of 10.39% from the current price of $154.58. For more details, explore the Johnson & Johnson (JNJ) Forecast page.
The consensus among 26 brokerage firms positions Johnson & Johnson (JNJ, Financial) with an average brokerage recommendation of 2.3, which aligns with an "Outperform" status. The recommendation scale spans from 1 (Strong Buy) to 5 (Sell), indicating a generally favorable outlook.
Meanwhile, the GuruFocus analysis projects the estimated GF Value of Johnson & Johnson (JNJ, Financial) at $186.30 in one year, implying a notable upside of 20.52% from the current price of $154.58. The GF Value represents GuruFocus' intrinsic value estimation, grounded in historical trading multiples and projected business performance. For further in-depth data, visit the Johnson & Johnson (JNJ) Summary page.
